查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2008491

止吐藥市場：2026-2032年全球市場預測（依適應症、藥物類別、給藥途徑、最終用戶和分銷管道分類）

Antiemetic Drugs Market by Indication, Drug Class, Route Of Administration, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，止吐藥市值將達到 64.4 億美元，到 2026 年將成長到 70.1 億美元，到 2032 年將達到 117.8 億美元，複合年成長率為 9.00%。

主要市場統計數據
基準年 2025 64.4億美元
預計年份：2026年 70.1億美元
預測年份 2032 117.8億美元
複合年成長率 (%) 9.00%

本次演講將介紹止吐療法，重點闡述其臨床重要性、不斷變化的患者需求以及創新與支持性護理的交匯點。

止吐治療處於臨床治療、病患體驗和商業策略的交會點。在現代腫瘤學、手術全期護理和放射治療中，臨床療效、耐受性和生活品質日益受到重視，止吐藥的作用也從輔助支持治療轉變為治療路徑的核心組成部分。因此，臨床醫生、保險公司和醫療服務提供者現在正從更廣泛的觀點評估止吐藥的選擇，包括給藥的便利性、安全性以及與多方面支持治療通訊協定的整合。

藥物創新、數位醫療的整合以及治療模式的轉變，推動了止吐療法的變革性變化。

止吐藥領域正經歷一場意義深遠的變革，這主要得益於藥理學、製劑科學和醫療服務模式的進步。近年來，更多標靶性藥物和聯合治療相繼問世，它們在增強止吐效果的同時，顯著降低了副作用。這些藥理學創新與製劑技術的改進相輔相成，提高了口服生物有效性，延長了治療時間。因此，臨床醫師現在可以根據治療強度、病患合併症和實際操作限制等因素，選擇更合適的治療方法。

評估 2025 年美國關稅對止吐藥供應鏈、定價趨勢、策略採購和生產韌性的累積影響。

2025年實施的關稅體系為包括止吐藥在內的所有藥品類別的供應鏈最佳化和商業規劃引入了新的變數。進口關稅和貿易政策的調整加劇了對全球籌資策略的審查，迫使製造商重新評估製造地。為此，多家公司加快制定緊急時應對計畫，以減少對單一國家供應基地的依賴，並降低價格和前置作業時間波動帶來的風險。

將適應症、藥物分類、給藥途徑、終端用戶行為和分銷管道聯繫起來的實用細分見解和策略規劃指導。

市場細分為將臨床需求轉化為產品、市場准入和商業策略提供了一個實用的架構。根據適應症的不同，化療引起的噁心嘔吐、術後噁心嘔吐和放射線治療引起的噁心嘔吐有不同的市場動態，每種適應症都有其獨特的療效、給藥時間和安全性要求。化療相關通訊協定通常需要合併多種藥物進行預防性給藥，並且需要可預測的藥物動力學。對於術後用藥，快速起效和適合短期住院至關重要。對於放射治療相關的噁心，在分次放射治療方案中可能需要長期控制。

區域洞察美洲、歐洲、中東和非洲以及亞太地區的趨勢如何影響取得、報銷、分銷和臨床引入。

區域趨勢對止吐藥的研發、核准、分銷和應用等各方面都具有顯著影響。在美洲，支付方的多樣性以及公私採購體系的混合，獎勵人們尋求能夠減少後續醫療保健支出的證據。因此，處方集納入止吐藥往往受到醫療保健總成本和供應可靠性的考慮。在北美，門診癌症治療和日間手術的增加，推動了對方便口服製劑和適合居家服用的緊湊包裝的需求。

來自主要企業的真知灼見，檢驗競爭定位、研發重點、策略聯盟、製造地和商業化策略。

止吐藥市場的競爭格局呈現出多種因素交織的態勢，包括成熟療法、學名藥的競爭，以及透過新配方和聯合治療實現的漸進式創新。那些透過長效配方、固定劑量組合藥物或便利包裝等方式維持差異化價值提案的公司，往往能夠獲得優先採購權和臨床醫師的支持。在研發、生產和分銷管道之間建立策略聯盟，能夠進一步加速市場進入，並降低執行風險。

為優先加強供應韌性、加速招募、最佳化分銷和以患者為中心的創新提出切實可行的建議。

領導者應優先考慮幾項影響深遠的舉措，以維持藥品供應、支持臨床醫生並創造商業性價值。首先，透過供應商多元化、建立策略性區域夥伴關係以及使用庫存視覺化工具來增強價值鏈韌性，從而能夠快速應對各種突發情況。其次，加速開發以患者為中心的製劑和包裝，以支持門診和居家照護下的給藥，從而使產品特性與不斷發展的護理路徑保持一致。

穩健的調查方法，結合了與專家的直接參與、對第二手資料的系統性審查、資料三角驗證、檢驗以及對限制的揭露。

本報告的分析整合了結構化的初級和二級調查方法，以確保方法的嚴謹性和實際相關性。初級研究包括對臨床專業人員、採購經理和銷售主管的訪談，以獲取有關處方行為、採購重點和供應鏈限制因素的第一手資訊。二級研究包括同行評審文獻、臨床指南分析、監管文件和公開的政策聲明，以闡明臨床和政策促進因素的背景。

為了使相關人員能夠充分了解止吐領域的挑戰和機遇，我們總結了策略挑戰、優先事項和考慮因素，形成了簡潔扼要的結論。

止吐治療領域融合了臨床需求、不斷演變的給藥模式和複雜的商業性環境，因此需要明確的策略規劃。能夠根據不斷變化的醫療環境（尤其是門診和居家給藥）調整產品特性，同時增強供應韌性的利益相關人員，更有能力滿足臨床醫生和支付方的期望。此外，提供能夠量化以患者為中心的獲益和營運成本降低的證據，仍然是將產品納入處方藥目錄和獲得合約的有力工具。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：止吐藥市場：依適應症分類

  • 化療引起的噁心和嘔吐
  • 術後噁心嘔吐
  • 放射線治療引起的噁心和嘔吐

第9章：止吐藥市場：依藥物類別分類

  • 皮質類固醇
  • 多巴胺拮抗劑
  • 神經激肽1受體拮抗劑
  • 血清素5-HT3受體拮抗劑

第10章：止吐藥市場：依給藥途徑分類

  • 靜脈
  • 口服

第11章 止吐藥市場：依最終用戶分類

  • 診所
  • 居家照護設施
  • 醫院

第12章：止吐藥市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章 止吐藥市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：止吐藥市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 止吐藥市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國止吐藥市場

第17章：中國止吐藥市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Acacia Pharma Limited
  • Akorn Operating Company LLC
  • Algen Healthcare Ltd.
  • Alkem Laboratories Ltd.
  • Cipla Limited
  • Dr. Reddy's Laboratories Limited
  • Fresenius Kabi Pte Ltd.
  • Glenmark Pharmaceuticals Limited
  • Global Calcium Private Limited
  • Helsinn Healthcare SA
  • Hikma Pharmaceuticals PLC
  • Lupin Limited
  • Merck KGaA
  • Novartis AG
  • Pax Healthcare
  • Pfizer Inc.
  • Sanofi SA
  • Saphnix Life Sciences
  • Scindia Pharma
  • Sun Pharmaceutical Industries Limited
  • Swastik Life Sciences
  • Teva Pharmaceuticals Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Viatris Inc.
  • Weefsel Pharma
Product Code: MRR-C002B1C996F2

The Antiemetic Drugs Market was valued at USD 6.44 billion in 2025 and is projected to grow to USD 7.01 billion in 2026, with a CAGR of 9.00%, reaching USD 11.78 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.44 billion
Estimated Year [2026] USD 7.01 billion
Forecast Year [2032] USD 11.78 billion
CAGR (%) 9.00%

Introduces antiemetic therapeutics, highlighting clinical importance, evolving patient needs, and the intersection of innovation and supportive care

Antiemetic therapeutics sit at the intersection of clinical care, patient experience, and commercial strategy. Modern oncology, perioperative medicine, and radiation therapy increasingly emphasize not only clinical efficacy but also tolerability and quality of life, elevating the role of antiemetics from supportive adjuncts to core components of treatment pathways. As a result, clinicians, payers, and providers now evaluate antiemetic choices through a broader lens that includes administration convenience, safety profiles, and integration with multimodal supportive care protocols.

Moreover, shifts in care delivery-most notably the expansion of outpatient chemotherapy, home-based infusion services, and ambulatory surgery centers-have altered expectations for route of administration and product packaging. Patients and clinicians demand reliable oral options that preserve efficacy while enabling adherence outside the hospital, and health systems prioritize interventions that reduce readmissions and improve throughput. Consequently, manufacturers and distributors must adapt commercial models to align with evolving procurement processes and clinician workflows.

Finally, regulatory clarity and guideline updates have reinforced evidence-driven prescribing, while reimbursement and contracting environments continue to shape formulary decisions. Taken together, these forces create both constraints and opportunities for developers, suppliers, and health systems seeking to improve supportive care outcomes and operational efficiency.

Transformative shifts in antiemetic therapy driven by pharmacologic innovation, digital care integration, and changing delivery models

The antiemetic landscape is undergoing substantive transformation driven by advances in pharmacology, formulation science, and care delivery models. Recent years have produced more targeted agents and combination regimens that enhance emetic control while reducing adverse effects, and these pharmacologic innovations are complemented by formulation improvements that expand oral bioavailability and prolong therapeutic windows. As a result, clinicians can select regimens that better match treatment intensity, patient comorbidities, and logistical constraints.

Concurrently, care models are shifting toward patient-centric approaches. Telehealth-enabled follow-up, remote symptom monitoring, and digital adherence tools are increasingly used to capture real-world tolerability and to guide supportive interventions. These digital adjuncts allow for earlier identification of breakthrough nausea and enable timely escalation or modification of antiemetic therapy, improving outcomes and reducing the burden on acute care services. Parallel to this, supply chain resilience and strategic sourcing have risen as priorities for manufacturers and health systems, prompting investment in regional manufacturing capacity and diversified supplier networks.

In addition, payer and hospital procurement strategies now center on total cost of care metrics and patient-reported outcomes. This change favors interventions that reduce downstream resource utilization, such as unscheduled clinic visits and prolonged hospital stays, thereby elevating the commercial value of antiemetics that demonstrably improve tolerability and adherence. Collectively, these shifts are reshaping clinical practice and the competitive landscape, requiring stakeholders to realign R&D, market access, and commercialization strategies.

Assessing the cumulative impact of United States tariffs in 2025 on antiemetic supply chains, pricing dynamics, strategic sourcing, and manufacturing resilience

The tariff landscape introduced in 2025 ushered in a new set of variables for supply chain optimization and commercial planning across pharmaceutical categories, including antiemetics. Import duties and trade policy adjustments have increased scrutiny of global sourcing strategies, prompting manufacturers to re-evaluate where active pharmaceutical ingredients, excipients, and finished-dose manufacturing occur. In response, several firms accelerated contingency planning to reduce dependence on single-country supply nodes and to mitigate price and lead-time volatility.

Consequently, procurement teams and contract manufacturers have prioritized supplier diversification and dual-sourcing arrangements to preserve continuity of supply. These actions include qualification of regional contract manufacturing organizations, increased inventory buffering for critical components, and renegotiation of long-term contracts to incorporate tariff contingency clauses. At the same time, regulatory and quality oversight remain central; localization efforts must satisfy stringent manufacturing standards while minimizing disruptions to existing regulatory filings and distribution agreements.

From a strategic perspective, companies have adopted multiple risk-mitigation tactics that include nearshoring select production steps, investing in supply visibility tools, and coordinating closely with distribution partners to optimize route-to-market logistics. Payers and health systems, for their part, are increasingly focused on predictable supply and stable pricing as criteria for formulary placement and preferred contracting. In sum, the cumulative tariff impacts of 2025 have strengthened incentives for resilient, transparent, and regionally balanced manufacturing and procurement strategies.

Actionable segmentation insights connecting indication, drug class, administration route, end user behavior, and distribution channel guidance for strategy

Segmentation provides a practical framework to translate clinical needs into product, access, and commercial strategies. Based on Indication, market dynamics differ across chemotherapy-induced nausea and vomiting, post-operative nausea and vomiting, and radiation-induced nausea and vomiting, each presenting unique efficacy, timing, and safety imperatives. Chemotherapy-associated protocols often require multi-agent prophylaxis and predictable pharmacokinetics; post-operative use emphasizes rapid onset and suitability for short-stay settings; radiation-related nausea may demand extended-duration control for fractionated regimens.

Based on Drug Class, decision criteria and formulary placement pivot on attributes of corticosteroids, dopamine antagonists, neurokinin 1 receptor antagonists, and serotonin 5-HT3 receptor antagonists, with each class offering distinct benefit-risk trade-offs that influence regimen selection and combination approaches. Corticosteroids provide broad antiemetic augmentation but carry systemic effects that must be managed. Dopamine antagonists supply alternative mechanisms but demand attention to neurologic tolerability. Neurokinin 1 receptor antagonists and serotonin 5-HT3 receptor antagonists remain foundational for guideline-driven prophylaxis, and evolving formulations aim to optimize adherence and convenience.

Based on Route Of Administration, outcomes and channel strategies diverge between intravenous and oral options, shaping procurement preferences in hospitals and outpatient settings and influencing product development priorities. Based on End User, clinics, home care settings, and hospitals each impose different stocking practices, dispensing workflows, and clinician touchpoints that affect uptake and adherence. Based on Distribution Channel, hospital pharmacy, online pharmacy, and retail pharmacy routes carry distinct reimbursement pathways, inventory models, and patient access considerations that determine where and how products gain traction. By integrating these segmentation lenses, stakeholders can align clinical evidence generation, commercial messaging, and distribution tactics to the real-world requirements of each use case.

Regional insights on how Americas, Europe, Middle East & Africa, and Asia-Pacific dynamics influence access, reimbursement, distribution, and clinical adoption

Regional dynamics materially influence every aspect of antiemetic development, approval, distribution, and adoption. In the Americas, diverse payer landscapes and a mix of public and private procurement systems create incentives for evidence demonstrating reductions in downstream healthcare utilization; consequently, formulary positioning often hinges on total cost of care narratives and supply reliability. In North America, outpatient oncology and ambulatory surgery growth have elevated demand for convenient oral options and compact packaging suited to home administration.

In Europe, Middle East & Africa, regulatory harmonization across jurisdictions and national procurement processes shape entry strategies, with reimbursement timelines and health technology assessment outcomes guiding commercialization sequencing. Local manufacturing and distribution partnerships frequently reduce lead times and support compliance with regional procurement rules, and in some countries system-level purchasing emphasizes affordable, generic-friendly options.

In Asia-Pacific, rapid expansion of oncology services, increased uptake of outpatient care models, and heterogeneous regulatory pathways present both opportunity and complexity. Investment in regional manufacturing infrastructure and strategic partnerships can accelerate access, while tailored clinical evidence that reflects local treatment paradigms supports uptake. Across all regions, distribution channel evolution and digital health adoption vary markedly, and stakeholders must calibrate pricing, stakeholder engagement, and supply strategies to local drivers to secure sustainable access and clinical integration.

Key company insights examining competitive positioning, R&D priorities, strategic partnerships, manufacturing footprint, and commercialization strategies

Competitive dynamics in the antiemetic space reflect a blend of established therapeutic classes, generics competition, and incremental innovation through new formulations and combination regimens. Companies that sustain differentiated value propositions-whether through long-acting formulations, fixed-dose combinations, or convenience-focused packaging-tend to secure preferential procurement and clinician loyalty. Strategic partnerships across development, manufacturing, and distribution channels further accelerate market entry and reduce execution risk.

R&D priorities now emphasize not only mechanistic efficacy but also tolerability, dosing convenience, and evidence of downstream healthcare savings. This shift has stimulated cross-functional collaborations between clinical teams and real-world evidence groups to capture patient-reported outcomes and healthcare utilization endpoints. In addition, manufacturing footprint and supply chain transparency have become competitive differentiators; companies that can demonstrate robust, diversified supply and quick replenishment capabilities gain favor with large hospital systems and integrated delivery networks.

Commercial models increasingly blend direct-to-provider engagement, digital tools to support patient adherence, and targeted contracting with payers and group purchasing organizations. Firms that articulate clear value across clinical, operational, and economic dimensions, and that can adapt to regional procurement nuances, will be better positioned to convert clinical advantage into sustainable commercial performance.

Actionable recommendations to strengthen supply resilience, accelerate adoption, optimize distribution, and prioritize patient-centric innovation

Leaders should prioritize a short set of high-impact actions to preserve access, support clinicians, and capture commercial value. First, reinforce supply chain resilience through supplier diversification, strategic regional partnerships, and inventory visibility tools that enable rapid response to disruption. Second, accelerate development of patient-centric formulations and packaging that support outpatient and home-care administration, thereby aligning product attributes with evolving care pathways.

Third, invest in evidence generation that demonstrates not only symptom control but also reductions in downstream resource use and improvements in patient-reported outcomes; such evidence strengthens negotiations with payers and hospital procurement teams. Fourth, deploy digital adherence and remote monitoring solutions to support real-world use, reduce breakthrough events, and collect post-launch data that inform iterative product positioning. Fifth, refine commercial approaches to suit distribution channels-hospital pharmacy, online pharmacy, and retail pharmacy-ensuring that reimbursement, logistics, and clinician engagement align with channel-specific expectations.

Finally, integrate tariff and trade policy risk into strategic planning by considering nearshoring, contractual tariff protections, and scenario-based financial modeling. By sequencing these actions with clear owners and measurable KPIs, organizations can move from reactive to proactive management of clinical, operational, and commercial risks.

Robust research methodology combining primary expert engagement, structured secondary review, data triangulation, validation, and limitation disclosure

The analysis underpinning this report integrates structured primary and secondary research practices to ensure methodological rigor and practical relevance. Primary inputs include interviews with clinical experts, procurement leaders, and commercial executives to capture experiential insights on prescribing behavior, purchasing priorities, and supply chain constraints. Secondary review comprises peer-reviewed literature, clinical guideline analyses, regulatory documentation, and publicly available policy statements to contextualize clinical and policy drivers.

Data triangulation is applied across sources to validate thematic findings and to reconcile divergent perspectives. Quality controls included standardized interview guides, independent coding of qualitative inputs, and cross-verification of critical claims with multiple expert respondents. Limitations are acknowledged, including potential variability in regional practice patterns and the evolving nature of policy interventions. These limitations are disclosed transparently, and findings are presented with caveats where applicable to support informed decision-making.

Concise conclusion synthesizing strategic imperatives, priorities, and considerations to guide stakeholders through antiemetic challenges and opportunities

The antiemetic therapeutic area presents a convergence of clinical need, delivery model change, and commercial complexity that demands strategic clarity. Stakeholders who align product attributes with evolving care settings-particularly outpatient and home-based administration-while reinforcing supply resilience will be better positioned to meet clinician and payer expectations. Meanwhile, evidence generation that quantifies patient-centered benefits and operational savings remains a powerful lever for formulary inclusion and contracting.

Looking ahead, organizations should balance near-term operational actions with longer-term investments in formulation innovation and digital support tools. By doing so, they can reduce acute care utilization, improve patient adherence, and create defensible differentiation against generic competition. Ultimately, the most successful stakeholders will be those that integrate clinical insight, supply chain agility, and pragmatic commercialization into a cohesive strategy that responds to both immediate pressures and enduring patient needs.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Antiemetic Drugs Market, by Indication

  • 8.1. Chemotherapy-Induced Nausea And Vomiting
  • 8.2. Post-Operative Nausea And Vomiting
  • 8.3. Radiation-Induced Nausea And Vomiting

9. Antiemetic Drugs Market, by Drug Class

  • 9.1. Corticosteroids
  • 9.2. Dopamine Antagonists
  • 9.3. Neurokinin 1 Receptor Antagonists
  • 9.4. Serotonin 5-HT3 Receptor Antagonists

10. Antiemetic Drugs Market, by Route Of Administration

  • 10.1. Intravenous
  • 10.2. Oral

11. Antiemetic Drugs Market, by End User

  • 11.1. Clinics
  • 11.2. Home Care Settings
  • 11.3. Hospitals

12. Antiemetic Drugs Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy

13. Antiemetic Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Antiemetic Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Antiemetic Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Antiemetic Drugs Market

17. China Antiemetic Drugs Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Acacia Pharma Limited
  • 18.6. Akorn Operating Company LLC
  • 18.7. Algen Healthcare Ltd.
  • 18.8. Alkem Laboratories Ltd.
  • 18.9. Cipla Limited
  • 18.10. Dr. Reddy's Laboratories Limited
  • 18.11. Fresenius Kabi Pte Ltd.
  • 18.12. Glenmark Pharmaceuticals Limited
  • 18.13. Global Calcium Private Limited
  • 18.14. Helsinn Healthcare S.A.
  • 18.15. Hikma Pharmaceuticals PLC
  • 18.16. Lupin Limited
  • 18.17. Merck KGaA
  • 18.18. Novartis AG
  • 18.19. Pax Healthcare
  • 18.20. Pfizer Inc.
  • 18.21. Sanofi S.A.
  • 18.22. Saphnix Life Sciences
  • 18.23. Scindia Pharma
  • 18.24. Sun Pharmaceutical Industries Limited
  • 18.25. Swastik Life Sciences
  • 18.26. Teva Pharmaceuticals Industries Ltd.
  • 18.27. Torrent Pharmaceuticals Ltd.
  • 18.28. Viatris Inc.
  • 18.29. Weefsel Pharma

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTIEMETIC DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANTIEMETIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ANTIEMETIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ANTIEMETIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY POST-OPERATIVE NAUSEA AND VOMITING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY POST-OPERATIVE NAUSEA AND VOMITING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY POST-OPERATIVE NAUSEA AND VOMITING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY RADIATION-INDUCED NAUSEA AND VOMITING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY RADIATION-INDUCED NAUSEA AND VOMITING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY RADIATION-INDUCED NAUSEA AND VOMITING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY NEUROKININ 1 RECEPTOR ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY NEUROKININ 1 RECEPTOR ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY NEUROKININ 1 RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS ANTIEMETIC DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE, MIDDLE EAST & AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. MIDDLE EAST ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. MIDDLE EAST ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 85. MIDDLE EAST ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 91. AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 92. AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. ASEAN ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. ASEAN ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 104. ASEAN ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 105. ASEAN ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 106. ASEAN ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. ASEAN ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. GCC ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GCC ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 110. GCC ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 111. GCC ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 112. GCC ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. GCC ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPEAN UNION ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPEAN UNION ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPEAN UNION ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPEAN UNION ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPEAN UNION ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPEAN UNION ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. BRICS ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. BRICS ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 122. BRICS ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 123. BRICS ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 124. BRICS ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. BRICS ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. G7 ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. G7 ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 128. G7 ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 129. G7 ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 130. G7 ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. G7 ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. NATO ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. NATO ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 134. NATO ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 135. NATO ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 136. NATO ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. NATO ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. UNITED STATES ANTIEMETIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 140. UNITED STATES ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 141. UNITED STATES ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 142. UNITED STATES ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 143. UNITED STATES ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. UNITED STATES ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. CHINA ANTIEMETIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 146. CHINA ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 147. CHINA ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 148. CHINA ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 149. CHINA ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. CHINA ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)